使用本网站需要启用 JavaScript, 请启用后刷新页面获得更好的体验
登录
注册
首页
个人居家检测
临床应用研究
科研合作项目
合作与服务
社区
纯合片段分析
姓氏祖源
祖源平均脸
基因关系
基因保险助手
原始数据
使用 WeGene 需要启用 Cookies, 请启用后刷新页面获得更好的体验
社区首页
小组
恢复能力
恢复能力
发起讨论
恢复能力
0 个讨论
只看精华帖
按热门排序
按最新排序
暂时没有精华内容
发起讨论
恢复能力
0 个讨论
相关基因
HIF1A
位点：RS11549465
NAT2
位点：RS1208
AMPD1
位点：RS17602729
PPARD
位点：RS2016520
Nagy G, et al. Association of hypoxia inducible factor-1 alpha gene polymorphism with both type 1 and type 2 diabetes in a Caucasian (Hungarian) sample. 2009
Torres O, et al. Lack of association between hypoxia inducible factor-1 alpha gene polymorphisms and biopsy-proven giant cell arteritis. 2010
Knechtel G, et al. Single nucleotide polymorphisms in the hypoxia-inducible factor-1 gene and colorectal cancer risk. 2010
Ruiz-Tovar J, et al. Association of thymidylate synthase and hypoxia inducible factor-1alpha DNA polymorphisms with pancreatic cancer. 2012
Hlatky MA, et al. Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease. 2007
Heino S, et al. Non-synonymous sequence variants within the oxygen-dependent degradation domain of the HIF1A gene are not associated with pre-eclampsia in the Finnish population. 2008
Droma Y, et al. Two hypoxia sensor genes and their association with symptoms of acute mountain sickness in Sherpas. 2008
Wipff J, et al. Association of hypoxia-inducible factor 1A (HIF1A) gene polymorphisms with systemic sclerosis in a French European Caucasian population. 2015
Konac E, et al. Genetic variations in the hypoxia-inducible factor-1alpha gene and lung cancer. 2009
Zheng ZL, et al. Genetic polymorphisms of hypoxia-inducible factor-1 alpha and cardiovascular disease in hemodialysis patients. 2009
Eynon N, et al. Is the interaction between HIF1A P582S and ACTN3 R577X determinant for power/sprint performance? 2010
Emanuele E, et al. A multilocus candidate approach identifies ACE and HIF1A as susceptibility genes for cellulite. 2010
Döring F, et al. A common haplotype and the Pro582Ser polymorphism of the hypoxia-inducible factor-1alpha (HIF1A) gene in elite endurance athletes. 2010
Xu CF, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. 2010
Kim SJ, et al. The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients. 2010
Qin C, et al. The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma. 2012
Gerger A, et al. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. 2011
Li P, et al. Genetic polymorphisms in HIF1A are associated with prostate cancer risk in a Chinese population. 2012
Bravatà V, et al. Genotyping analysis and ¹⁸FDG uptake in breast cancer patients: a preliminary research. 2013
Fu SL, et al. A polymorphism in the 3' untranslated region of Hypoxia-Inducible Factor-1 alpha confers an increased risk of cervical cancer in a Chinese population. 2013
Fraga A, et al. The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration. 2014
Fu SL, et al. A polymorphism in the 3' untranslated region of Hypoxia-Inducible Factor-1 alpha confers an increased risk of cervical cancer in a Chinese population. 2015
Feng CC, et al. Lack of association between the polymorphisms of hypoxia-inducible factor 1A (HIF1A) gene and SLE susceptibility in a Chinese population. 2014
Liu J, et al. 1790 G/A polymorphism, but not 1772 C/T polymorphism, is significantly associated with cancers: an update study. 1772
Mikuls TR, et al. Impact of interactions of cigarette smoking with NAT2 polymorphisms on rheumatoid arthritis risk in African Americans. 2012
Hein DW, et al. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. 2012
Buxens A, et al. Can we predict top-level sports performance in power vs endurance events? A genetic approach. 2011
Crabtree MD, et al. Analysis of candidate modifier loci for the severity of colonic familial adenomatous polyposis, with evidence for the importance of the N-acetyl transferases. 2004
García-Closas M, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. 2005
Patin E, et al. Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. 2006
Morton LM, et al. Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. 2006
Dai Z, et al. Genotyping panel for assessing response to cancer chemotherapy. 2008
Agúndez JA, et al. Unraveling ambiguous NAT2 genotyping data. 2008
Walraven JM, et al. Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. 2008
Luca F, et al. Multiple advantageous amino acid variants in the NAT2 gene in human populations. 2008
Chang MH, et al. Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994. 2009
Sabbagh A, et al. Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data. 2009
Vatsis KP, et al. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. 1991
Grant DM, et al. A simple test for acetylator phenotype using caffeine. 1984
Cascorbi I, et al. NAT2*12A (803A-->G) codes for rapid arylamine n-acetylation in humans. 1996
Gil J, et al. CYP1A1 Ile462Val polymorphism and colorectal cancer risk in Polish patients. 2014
Genetta T, et al. A novel bipartite intronic splicing enhancer promotes the inclusion of a mini-exon in the AMP deaminase 1 gene. 2001
Lucia A, et al. C34T mutation of the AMPD1 gene in an elite white runner. 2006
Anderson JL, et al. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. 2000
Ramakers BP, et al. Circulating adenosine increases during human experimental endotoxemia but blockade of its receptor does not influence the immune response and subsequent organ injury. 2011
Yamaguchi-Kabata Y, et al. Distribution and effects of nonsense polymorphisms in human genes. 2008
Won HH, et al. Cataloging coding sequence variations in human genome databases. 2008
Ruiz JR, et al. Is there an optimum endurance polygenic profile? 2009
Eynon N, et al. Genes for elite power and sprint performance: ACTN3 leads the way. 2013
Hennis PJ, et al. Genetic factors associated with exercise performance in atmospheric hypoxia. 2015
Gallicchio L, et al. Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland. 1989
Burch LR, et al. A single nucleotide polymorphism on exon-4 of the gene encoding PPARdelta is associated with reduced height in adults and children. 2009
Ahmetov II, et al. The combined impact of metabolic gene polymorphisms on elite endurance athlete status and related phenotypes. 2009
Wei XL, et al. The peroxisome proliferator-activated receptor delta +294T > C polymorphism and alcohol consumption on serum lipid levels. 2011
Holzapfel J, et al. PPARD haplotype influences cholesterol metabolism but is no risk factor of Alzheimer's disease. 2006
Chang SC, et al. Polymorphism of genes related to insulin sensitivity and the risk of biliary tract cancer and biliary stone: a population-based case-control study in Shanghai, China. 2008
Sáez ME, et al. Interaction between Calpain 5, Peroxisome proliferator-activated receptor-gamma and Peroxisome proliferator-activated receptor-delta genes: a polygenic approach to obesity. 2008
Hsing AW, et al. Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China. 2008
Eynon N, et al. Is there an interaction between PPARD T294C and PPARGC1A Gly482Ser polymorphisms and human endurance performance? 2009
Burch LR, et al. Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may influence lipid response to statin therapy in humans: a genetics of diabetes audit and research Tayside study. 2010
Halvorsen M, et al. Disease-associated mutations that alter the RNA structural ensemble. 2010
Hildebrandt MA, et al. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. 2010
Bouchard-Mercier A, et al. Effects of peroxisome proliferator-activated receptors, dietary fat intakes and gene-diet interactions on peak particle diameters of low-density lipoproteins. 2011
Luo WS, et al. [Association of both peroxisome proliferator-activated receptor, gene-gene interactions and the body mass index]. 2012
Luo W, et al. Association of peroxisome proliferator-activated receptor α/δ/γ with obesity, and gene-gene interaction, in the Chinese Han population. 2013
Ye H, et al. Genetic associations with coronary heart disease: meta-analyses of 12 candidate genetic variants. 2013
Yu H, et al. [Effects related to gene-gene interactions of peroxisome proliferator-activated receptor on essential hypertension]. 2013
Gu SJ, et al. [Gene-gene interactions among the peroxisome proliferator-activated receptor polymorphisms for hypertriglyceridemia]. 2012
Yin RX, et al. Interactions of several single nucleotide polymorphisms and high body mass index on serum lipid traits. 2013
纯合片段分析
姓氏祖源
祖源平均脸
基因关系
基因保险助手
原始数据
深圳市市场监督管理局企业主体身份公示
中文
English